Lymphoma

Disease Group

Lymphoma

Disease Group Profile

Our group focuses on developing novel early phase trials for all lymphoma subtypes, and in partnering with industry on practice changing phase 3 clinical trials. Our members include junior and senior faculty from both academic and community institutions and collaboration within the group is encouraged. We currently have trials active or in development in Hodgkin lymphoma, Mantle Cell lymphoma, and DLBCL. We hope to expand in the areas of indolent lymphomas and T cell lymphomas.

Disease Group Leaders

Catherine Diefenbach, M.D.

NYU

Catherine Diefenbach, M.D. is an Associate Professor in the Division of Hematology and Medical Oncology in the NYU Perlmutter Cancer Center (PCC) at NYU Langone Health, the Clinical Director of Lymphoma, and the Translational Director of Hematology, and the Co-Chair of the Lymphoma Committee of the ACCRU network. Her research focuses on the relationship between systemic immunity, and tumor microenvironment and spans from investigator initiated clinical trials correlative science, to non-therapeutic investigations in collaboration with basic scientists.

Disease Group Clinical Trials

ACCRU-LY-1804

Modified VR-CAP and Acalabrutinib As Induction Therapy for Transplant-Eligible Patients with Mantle Cell Lymphoma

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma »

ACCRU-LY-1806

A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma »

ACCRU-LY-2101

Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study with Safety Lead-in

ACCRU-LY-2102

A Phase 2 Study of the Combination of Glofitimab and Tafasitamab as Second Line Salvage in Relapsed or Refractory Diffuse Large B-cell Lymphoma

ACCRU-LY-1601

A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy with or without Brentuximab Vedotin plus Nivolumab Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma »

ACCRU-LY-2001

A prospective observational study of patients with B-cell hematologic malignancies on ibrutinib therapy who are infected with coronavirus disease 2019 (COVID-19)

CC-5013-NHL-007

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refrac tory Indolent Lymphoma (The AUGMENT Study)

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin’s Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT) »

MC0485

A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20 B-Cell Non-Hodgkins Lymphoma

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma »

RC0783

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma »

RU051417I

Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma »

RU051505I

Phase II, Multi- center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the age of 60 Years or Unable to Receive Standard ABVD Chemotherapy

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma »